Recombinant adenoviruses and use thereof
AssigneesBeth Israel Deaconess Medical Center, Inc., Washington University
InventorsDan H. Barouch, Herbert Virgin, IV, Peter Abbink
Life of this patent
Estimating the term…
Abstract
The present invention relates to recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are novel simian adenoviruses having a low seroprevalence and high immunogenicity relative to other adenoviruses and vectors thereof. The invention also provides methods for production of the adenoviruses and for the treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human).
Claims44
A recombinant adenovirus comprising a nucleotide sequence having
- 90% or greater sequence identity over the entire sequence of SEQ ID NO:
- 11, or a complementary sequence to a nucleotide sequence having at least 90% sequence identity to SEQ ID NO:
- 11 over the entire sequence of SEQ ID NO:
- 11;
- wherein said recombinant adenovirus comprises a deletion in or of an E1 region, said deletion rendering said recombinant adenovirus a replication-defective virus.
A method of producing a recombinant adenovirus comprising transfecting a cell with a) an isolated polynucleotide comprising a nucleotide sequence having at least 90% or greater sequence identity to SEQ ID NO:
- 11 over the entire sequence of SEQ ID NO:
- 11, or a complementary sequence to a nucleotide sequence having at least 90% or greater sequence identity to SEQ ID NO:
- 11 over the entire sequence of SEQ ID NO:
- 11, or identical to, or the complementary sequence to, SEQ ID NO:
- 2, or b) a recombinant vector comprising said polynucleotide;
- culturing said cell in a suitable medium to allow replication of said polynucleotide or said vector in said cell;
- and harvesting said recombinant adenovirus from said cell and/or from said medium.
Dependencies are inferred from the claim text.